51% of its active products are in Early Phase 1 or Phase 1.
See where the pipeline is concentrating.
Explore active products and interventions across clinical stages, technology families, diseases, companies, and partnerships.
Highest active phase per asset · 65 not assigned
Every product, positioned in context.
Start with the complete product landscape. Then use the structured panels below to compare stages, technologies, emerging approaches, and the organizations active in each area.
How technologies change across clinical stages.
29% of its active products have reached Phase 3.
Non-industry-led products that name an industry collaborator.
Products remain outside a specific technology family and stay visible.
Where biological research is gathering momentum.
Compare complete five-year cohorts by disease, reported phase, and industry involvement. This is the first historical view built from the reviewed all-status registry spine.
Enough context to read the numbers correctly.
Counts distinguish product groups, source asset records, product–indication links, and trials. Technology labels come from registry descriptions; sourced technical claims retain their original quotations.
- 01Count the right unit
The stage matrix counts each product once at its highest active phase. A separate program lens will count each indication.
- 02Keep uncertainty visible
Unclassified assets and unassigned stages remain in the totals instead of being silently distributed into a category.
- 03Open the source record
Product pages retain registry links and verbatim quotations for public technical claims. Browse the records.